Zobrazeno 1 - 10
of 103
pro vyhledávání: '"J F Rahier"'
Autor:
M Truyens, T Lobaton, A Peeters, M Ferrante, S Vermeire, P Bossuyt, L Pouillon, P Dewint, A Cremer, H Peeters, G Lambrecht, E Louis, J F Rahier, O Dewit, V Muls, T Holvoet, L Vandermeulen, G B Gonzales, D Laukens, M De Vos
Publikováno v:
Journal of Crohn's and Colitis. 16:i029-i032
Background Fatigue is highly prevalent in patients with IBD independent of the disease status but treatment options remain limited. A potential mediator in the pathophysiology of fatigue is tryptophan (Trp), a precursor of serotonin. Recently, reduce
Autor:
G Le Cosquer, C Gilletta, A Amiot, P Rivière, M Nachury, C Rouillon, Y Bouhnik, V Abitbol, S Nancey, M Fumery, G Savoye, A Biron, L Picon, L Peyrin-Biroulet, M Vidon, C Reenaers, M Simon, B Caron, M Serrero, R Altwegg, A Benezech, F Goutorbe, J F Rahier, L Beaugerie, A L Pelletier, L Caillo, D Laharie, F Poullenot
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Background Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD) unrelated to the disease or its treatment (Poullenot F et al. JCC 2022). The main aim of our study was to assess the risk of incident c
Autor:
J.-F. Colombel, An Outtier, P Bossuyt, Triana Lobaton, F Baert, Marie Truyens, A Cremer, Marc Ferrante, L Goessens, E Macken, J F Rahier, B Strubbe
Publikováno v:
Journal of Crohn's and Colitis. 14:S440-S442
Background Few data are available regarding the combination of biological therapies (anti-TNF, anti-integrin, anti-interleukins (IL4, 12/23, 17A, 23)) or with a small molecule in patients with IBD. We here report the safety and efficacy of combining
Autor:
Joris Dutré, Evelien Humblet, S Vieujan, Fazia Mana, O. Dewit, N Schoofs, A Cremer, F Baert, S Delen, J F Rahier, F D'Heygere, Philip Caenepeel, S De Coninck, Sophie Dewit, A El Nawar, Clara Thienpont, Annelies Verreth, S Vanden Branden, J L Coenegrachts, Denis Franchimont, P Bossuyt, P Van Hootegem, Michaël Somers, A Vijverman, E Macken, Triana Lobaton, D Staessen, Barbara Willandt
Publikováno v:
Journal of Crohn's and Colitis. 14:S384-S386
Background Tofacitinib, an oral small molecule Janus kinase inhibitor, has been approved in 2018 for the treatment of moderate to severe ulcerative colitis (UC) in Europe. We report on real-world short-term efficacy and safety data from a multicenter
Autor:
P M Eder, B Verstock, E Culver, G Dragoni, L I Kredel, A G G de Paredes, M Kaniewska, H Leibovitzh, G Oracz, D G Ribaldone, J Wypych, A Badaoui, J F Rahier, C Bezzio, P Bossuyt, K Falloon, C F Vozzo, T Jess, L Larsen, S S Olensen, T Starzyńska, M Chaparro, D Dror, P Ellul, I Gromny, K Maciejewska, N Peleg, A B G Shitrit, Ł Szwed, R Talar-Wojnarowska, Y Snir, E Zittan, I Goren
Publikováno v:
Journal of Crohn's and Colitis. 16:i301-i302
Background Autoimmune pancreatitis (AIP) is an uncommon inflammatory disorder that may accompany inflammatory bowel disease (IBD). The clinical relevance of AIP-IBD coexistence, therapeutic strategies, and long-term outcomes are scarcely known. Metho
Autor:
Andreia Albuquerque, Stephan R. Vavricka, L. de Ridder, Bram Verstockt, Hannah Gordon, Christian Maaser, Francis A Farraye, Maria Esteve, Torsten Kucharzik, N. Viget, Yamile Zabana, Candida Abreu, Carlos Taxonera, Michael Scharl, Konstantinos Karmiris, M Toruner, Uri Kopylov, Eithne MacMahon, Lydjie Tremblay, Pierre Ellul, T Greuter, Julien Kirchgesner, J F Rahier, Mariangela Allocca, Fernando Magro
Publikováno v:
Journal of Crohn's & colitis, Vol. 15, no. 6, p. 879-913 (2021)
INTRODUCTION : The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e27e8b77048a759a20cccb267047848
https://hdl.handle.net/2078.1/245437
https://hdl.handle.net/2078.1/245437
Autor:
J F Rahier, Richard B. Gearry, Ryan C. Ungaro, Flavio Steinwurz, Walter Reinisch, Michele Kissous-Hunt, Michael D. Kappelman, Gilaad G. Kaplan, Erica J. Brenner, Manasi Agrawal, J.-F. Colombel, James D. Lewis, Xiang Zhang, S. C. Ng
Publikováno v:
Journal of Crohn's & Colitis
Background Prior data have suggested that 5-aminosalicylates (5-ASA) may be associated with an increased risk of severe COVID-19 among inflammatory bowel disease (IBD) patients. We aimed to evaluate the association of 5-ASA with severe COVID-19 in a
Autor:
Stephan R. Vavricka, Hannah Gordon, Michel Adamina, Silvio Danese, N. Viget, Britta Siegmund, Fernando Magro, Laurent Peyrin-Biroulet, Torsten Kucharzik, S. Leone, Eithne MacMahon, J F Rahier, Ailsa Hart, C.J. van der Woude, Cândida Abreu
Publikováno v:
Journal of Crohns and Colitis
Journal of Crohn's and Colitis, 14, S798-S806. Oxford University Press
Journal of Crohn's and Colitis, 14, S798-S806. Oxford University Press
Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal
Publikováno v:
Journal of Crohn's & colitis, Vol. 14, no. 1, p. 148-149 (2020)
Journal of Crohn's & colitis, (2019)
Journal of Crohn's & colitis, (2019)
To the Editor, We read with interest the case reported by Rawa-Gołębiewska et al.1 on the resolution of Cytomegalovirus [CMV] infection on vedolizumab [VZ] therapy. We experienced a similar case that adds two additional pieces of information. First
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c18a35127d580fd069d9f99102ca961
https://hdl.handle.net/2078.1/220333
https://hdl.handle.net/2078.1/220333
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.